Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 3/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 4/20 | 0.34 |
| ▸ | BCHE | P06276 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | SCN4A | P35499 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17041578 | 0.82 | ADRB2 (0.41) | LMNAPTGS1TRPA1CACNA1CHIF1A | |
| SCHEMBL13890678 | 0.81 | LMNA (0.58) | LMNAPTGS1TRPA1CACNA1CHTT | |
| SCHEMBL19317747 | 0.80 | LMNA (0.44) | LMNAPTGS1TRPA1CACNA1CHTT | |
| SCHEMBL598134 | 0.77 | LMNA (0.65) | LMNAPTGS1TRPA1CACNA1CHTT | |
| SCHEMBL25027728 | 0.76 | LMNA (0.41) | LMNAPTGS1TRPA1CACNA1CHTT | |
| SCHEMBL20676163 | 0.75 | LMNA (0.77) | LMNAPTGS1TRPA1CACNA1CHTT | |
| SCHEMBL22618958 | 0.74 | LMNA (0.40) | LMNAPTGS1TRPA1CACNA1CHTT | |
| SCHEMBL16511366 | 0.74 | LMNA (0.40) | LMNAPTGS1TRPA1CACNA1CHTT | |
| SCHEMBL12101199 | 0.74 | PTGS1 (0.59) | LMNAPTGS1TRPA1CACNA1CHTT | |
| SCHEMBL9452689 | 0.73 | LMNA (0.54) | LMNAPTGS1TRPA1CACNA1CHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3566719-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | Cerulean Pharma Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-8785488-B2 | Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity | EXELIXIS PATENT COMPANY LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120040985-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | EXELIXIS PATENT COMPANY LLC (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040985-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | GPR119, GLP1R, GCGR | LMNA 4313/4885PTGS1 205/4885TRPA1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.